Understanding how a gene called FOXA1 affects the immune system in prostate cancer
FOXA1 regulates cytokine signaling and immune landscape in prostate cancer through ARID1A
This research aims to understand how a specific gene, FOXA1, influences the immune system's response to prostate cancer, especially when treatments stop working.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-11145642 on NIH RePORTER |
What this research studies
Prostate cancer is very common, and while initial treatments often work, the cancer can become resistant, known as castration-resistant prostate cancer (CRPC). Unfortunately, newer immune therapies, which are very effective in other cancers, haven't worked well for CRPC. This is because CRPC tumors often have immune cells that suppress the body's natural defenses. We want to learn how a gene called FOXA1, which is often changed in CRPC, might be controlling these immune-suppressing cells and making the tumor environment less friendly to immune treatments.
Who could benefit from this research
Good fit: This foundational research is for future patients with castration-resistant prostate cancer who might benefit from improved immune therapies.
Not a fit: Patients whose prostate cancer is not castration-resistant or who do not have the specific genetic changes being studied may not directly benefit from this particular research.
Why it matters
Potential benefit: If successful, this work could lead to new ways to make existing immune therapies more effective for patients with advanced prostate cancer.
How similar studies have performed: While previous work has shown FOXA1's role in cancer spread, how it specifically regulates the immune landscape in prostate cancer is currently unknown and being explored here.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Yu, Jindan — Emory University
- Study coordinator: Yu, Jindan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.